Avita Medical Ltd. (AVMXY) Starts Presentation at LD Micro Conference

Avita Medical develops and distributes regenerative products for the treatment of a broad range of wounds, scars and skin defects. Avita’s patented and proprietary tissue‐culture, collection and application technology provides innovative treatment solutions derived from a patient’s own skin. The company’s lead product, ReCell Spray‐On Skin, is used in a wide variety of burns, plastic, reconstructive and cosmetic procedures. ReCell is patented, CE‐marked for Europe, TGA‐registered in Australia, and SFDA‐cleared in China. ReCell in the U.S., however is limited by federal law to investigational use. A phase III FDA trial is in process. For more information, visit the company’s website at www.avitamedical.com.